Literature DB >> 20392068

Hypopigmentary action of dihydropyranocoumarin D2, a decursin derivative, as a MITF-degrading agent.

Dong-Seok Kim1, So-Hee Park, Hyun-Kyung Lee, Soo-Jin Choo, Jee Hyun Lee, Gyu Yong Song, Ick-Dong Yoo, Sun-Bang Kwon, Jung-Im Na, Kyoung-Chan Park.   

Abstract

In this study, the decursin derivative dihydropyranocoumarin D2 (1) was selected for its effects on melanogenesis using a spontaneously immortalized mouse melanocyte cell line (Mel-Ab). The results showed that 1 effectively inhibited melanin synthesis in a concentration-dependent manner, but that it did not inhibit tyrosinase in a cell-free system. In addition, the changes in ERK, Akt, and microphthalmia-associated transcription factor (MITF) in response to treatment with 1 were assessed. The results revealed that ERK was dramatically up-regulated and MITF was down-regulated in response to treatment with 1, but that Akt was unchanged. Therefore, the effects of 1 on melanogenesis were examined in the absence or presence of PD98059 (a specific inhibitor of the ERK pathway). PD98059 restored hypopigmentation and the down-regulation of MITF induced by 1. Finally, MITF down-regulation by 1 was clearly restored by both chloroquine, a lysosomal proteolysis inhibitor, and MG132, a proteasome inhibitor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20392068     DOI: 10.1021/np900455j

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  2 in total

1.  Sesamol decreases melanin biosynthesis in melanocyte cells and zebrafish: Possible involvement of MITF via the intracellular cAMP and p38/JNK signalling pathways.

Authors:  Seung-hwa Baek; Sang-Han Lee
Journal:  Exp Dermatol       Date:  2015-07-14       Impact factor: 3.960

2.  Ssanghwa-tang, an oriental herbal cocktail, exerts anti-melanogenic activity by suppression of the p38 MAPK and PKA signaling pathways in B16F10 cells.

Authors:  Aeyung Kim; Nam-Hui Yim; Minju Im; Young Pil Jung; Chun Liang; Won-Kyung Cho; Jin Yeul Ma
Journal:  BMC Complement Altern Med       Date:  2013-08-28       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.